A shift in focus from weight loss to health gain reduces stigma for patients living with obesity
Evaluation may include assessment for conditions that impair weight loss (hypothyroidism, Cushing's syndrome, polycystic ovary syndrome) or worsen glycemic control (pancreatic insufficiency, medication interactions)
Side Effect Mitigation The primary motivation for microdosing is reducing adverse effects: Theoretical advantages: Lower peak concentrations reduce nausea intensity Gradual exposure allows GI adaptation Reduced gastroparesis severity Better maintenance of normal eating patterns 2
Higher-order thiol cell systemsthe metallothioneins, thioredoxins, and other redox regulator proteinsare ultimately regulated by GSH levels and the GSH/GSSG redox ratio
Four years later in 2021, the FDA gave the green light to another brand-name drug with semaglutide as the active ingredient: Wegovy, which was (and still is) approved for chronic weight management in people with either obesity (body mass index (BMI) of 30 or greater) or overweight with at least one weight-related medical condition, such as type 2 diabetes or high blood pressure